Envista Holdings Co. (NYSE:NVST) Given Average Rating of "Hold" by Analysts

Shares of Envista Holdings Co. (NYSE:NVST - Get Free Report) have been assigned an average rating of "Hold" from the fourteen analysts that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $20.21.

NVST has been the topic of a number of recent analyst reports. Robert W. Baird lifted their price objective on Envista from $17.00 to $22.00 and gave the stock a "neutral" rating in a research note on Thursday, October 31st. Leerink Partners upgraded Envista from an "underperform" rating to a "market perform" rating and lifted their target price for the stock from $16.00 to $23.00 in a report on Thursday, October 31st. Jefferies Financial Group boosted their price objective on Envista from $20.00 to $22.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. Mizuho started coverage on Envista in a report on Wednesday, December 4th. They set an "underperform" rating and a $20.00 price target for the company. Finally, Morgan Stanley upped their price target on Envista from $19.00 to $20.00 and gave the stock an "equal weight" rating in a report on Thursday, February 6th.

Envista Price Performance

NYSE:NVST traded down $0.55 during trading hours on Tuesday, hitting $20.91. The company's stock had a trading volume of 1,423,960 shares, compared to its average volume of 2,148,655. The stock has a fifty day simple moving average of $20.08 and a 200-day simple moving average of $19.46. The company has a market capitalization of $3.60 billion, a P/E ratio of -3.22, a PEG ratio of 1.29 and a beta of 1.34. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. Envista has a twelve month low of $15.15 and a twelve month high of $23.06.

Envista (NYSE:NVST - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, analysts anticipate that Envista will post 1 EPS for the current fiscal year.

Institutional Trading of Envista

A number of institutional investors have recently added to or reduced their stakes in the stock. Ariel Investments LLC lifted its holdings in Envista by 6.2% during the 4th quarter. Ariel Investments LLC now owns 12,059,624 shares of the company's stock worth $232,630,000 after purchasing an additional 699,625 shares in the last quarter. Nuance Investments LLC lifted its holdings in Envista by 4.4% during the 3rd quarter. Nuance Investments LLC now owns 7,346,534 shares of the company's stock worth $145,168,000 after purchasing an additional 308,221 shares in the last quarter. Franklin Resources Inc. increased its stake in Envista by 72.6% in the 4th quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company's stock worth $132,223,000 after acquiring an additional 2,882,844 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Envista by 19.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company's stock worth $130,440,000 after acquiring an additional 1,089,923 shares during the last quarter. Finally, Gates Capital Management Inc. increased its stake in Envista by 15.1% in the 4th quarter. Gates Capital Management Inc. now owns 4,694,148 shares of the company's stock worth $90,550,000 after acquiring an additional 615,577 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.